Director Christopher Gibson of Recursion Pharmaceuticals NASDAQ:RXRX, sold 40,000 shares of Class A Common Stock on January 5, 2026, at a price of $4.25, totaling $170,000. The transaction occurred as ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Wondering if Recursion ...

CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...

Finding the right book can make a big difference, especially when you’re just starting out or trying to get better. We’ve ...